A promising outlook for diabetic kidney disease

Mark Cooper, Annabelle M. Warren

Research output: Contribution to journalArticleOtherpeer-review

3 Citations (Scopus)

Abstract

In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.

Original languageEnglish
Pages (from-to)68-70
Number of pages3
JournalNature Reviews Nephrology
Volume15
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Cite this

Cooper, Mark ; Warren, Annabelle M. / A promising outlook for diabetic kidney disease. In: Nature Reviews Nephrology. 2019 ; Vol. 15, No. 2. pp. 68-70.
@article{9869f5dc8133408db4d4c5f76c36c995,
title = "A promising outlook for diabetic kidney disease",
abstract = "In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.",
author = "Mark Cooper and Warren, {Annabelle M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1038/s41581-018-0092-5",
language = "English",
volume = "15",
pages = "68--70",
journal = "Nature Reviews Nephrology",
issn = "1759-5061",
publisher = "Nature Publishing Group",
number = "2",

}

A promising outlook for diabetic kidney disease. / Cooper, Mark; Warren, Annabelle M.

In: Nature Reviews Nephrology, Vol. 15, No. 2, 01.02.2019, p. 68-70.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - A promising outlook for diabetic kidney disease

AU - Cooper, Mark

AU - Warren, Annabelle M.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.

AB - In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.

UR - http://www.scopus.com/inward/record.url?scp=85058272196&partnerID=8YFLogxK

U2 - 10.1038/s41581-018-0092-5

DO - 10.1038/s41581-018-0092-5

M3 - Article

VL - 15

SP - 68

EP - 70

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-5061

IS - 2

ER -